Conv. Plasma
Nigella Sativa

All vitamin D studies
Meta analysis
study COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

The effects of vitamin D therapy on outcomes for hispanic patients hospitalized for COVID-19

Shahid et al., Abstracts from the 2022 Annual Meeting of the Society of General Internal Medicine, Journal of General Internal Medicine, doi:10.1007/s11606-022-07653-8
Jun 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 38% Improvement Relative Risk Vitamin D for COVID-19  Shahid et al.  LATE TREATMENT Is late treatment with vitamin D beneficial for COVID-19? Retrospective 1,478 patients in the USA Lower mortality with vitamin D (p=0.001) Shahid et al., Abstracts from the 2022.., Jun 2022 Favorsvitamin D Favorscontrol 0 0.5 1 1.5 2+
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020
*, now with p < 0.00000000001 from 122 studies, recognized in 9 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments.
Retrospective 1,478 hospitalized Hispanic patients in the USA with 705 receiving vitamin D treatment, showing lower mortality with treatment in unadjusted results. Very minimal information is currently available.
Cholecalciferol was used in this study. Meta analysis shows that late stage treatment with calcitriol / calcifediol (or paricalcitol, alfacalcidol, etc.) is more effective than cholecalciferol: 69% [47‑82%] lower risk vs. 39% [27‑49%] lower risk. Cholecalciferol requires two hydroxylation steps to become activated - first in the liver to calcifediol, then in the kidney to calcitriol. Calcitriol, paricalcitol, and alfacalcidol are active vitamin D analogs that do not require conversion. This allows them to have more rapid onset of action compared to cholecalciferol. The time delay for cholecalciferol to increase serum calcifediol levels can be 2-3 days, and the delay for converting calcifediol to active calcitriol can be up to 7 days.
This is the 85th of 122 COVID-19 controlled studies for vitamin D, which collectively show efficacy with p<0.0000000001 (1 in 587 sextillion).
30 studies are RCTs, which show efficacy with p=0.0000032.
This study is excluded in the after exclusion results of meta analysis: minimal details provided.
risk of death, 38.0% lower, RR 0.62, p < 0.001, treatment 705, control 773.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shahid et al., 17 Jun 2022, retrospective, USA, peer-reviewed, 2 authors, dosage not specified.
This PaperVitamin DAll
Abstract: Abstracts from the 2022 Annual Meeting of the Society of General Internal Medicine J Gen Intern Med 37(Suppl 2):S129–S664 DOI: 10.1007/s11606-022-07653-8 © The Author(s), under exclusive licence to Society of General Internal Medicine 2022 THE EFFECTS OF VITAMIN D THERAPY ON OUTCOMES FOR HISPANIC PATIENTS HOSPITALIZED FOR COVID-19 Saqib Shahid1; Fatma Dihowm2 1 Department of Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 2 Internal Medicine, Texas Tech University Health Science Center, El paso, TX. (Control ID #3709726) BACKGROUND: The SARS-CoV-2 novel coronavirus that causes COVID19 has been shown to more severely affect individuals with underlying conditions, such as metabolic syndrome or diabetes. This is a reason why SARS-CoV-2 more severely affects populations at risk for these conditions, notably the Hispanic population. Vitamin D has been shown to be a positive immunomodulatory actor, shown to upregulate production of CAMP (cathelicidin antimicrobial peptide) and its effect on mitigating the severity of respiratory illnesses has been widely studied. Additionally, given vitamin D’s role in the functional regulation of pancreatic beta cells, this study aims to determine whether vitamin D plays a significant role in providing better outcomes for Hispanic patients with diabetes. Data will be gathered for patients treated at University Medical Center in El Paso, where the majority of the population treated is Hispanic, allowing us the opportunity to observe phenomena unique to this population. S194 METHODS: We collected data from the charts of 1,478 Hispanic patients who were hospitalized for COVID-19 at University Medical Center El Paso. Comparisons were made between patients who received VItamin D therapy (705) and those who did not (773). The main outcome that was assessed was mortality, as well as secondary outcomes such as length of hospital stay, need for supplemental oxygen upon discharge, and ICU admission. Further comparisons were made between patients who suffer from diabetes and those who do not. RESULTS: Our preliminary results by way of a univariate analysis show that patients who were given Vitamin D therapy during their hospitalization had significantly lower rates of mortality (p<0.001). Patients in the group that received Vitamin D therapy were 38% less likely to die during their hospital stay (p<0.001). We also discovered that patients admitted to UMC El Paso were significantly more likely to be given Vitamin D therapy if they presented with respiratory and GI symptoms (p<0.001). A multivariate analysis on the relationship between previous history of diabetes and the efficacy of Vitamin D therapy is pending. CONCLUSIONS: Our results show that Vitamin D therapy as a part of the treatment protocol for COVID-19 can significantly reduce mortality during hospitalization. As a result of the unique composition of our patient population, these findings can help build standards of practice that are applicable to the specific needs of Hispanic patients throughout the course of the pandemic. Because patients in the Hispanic population are more susceptible to severe symptoms due to their predisposition to comorbid conditions like diabetes, using protocols informed by evidence has the potential to prevent mortality on a large scale.
{ 'indexed': {'date-parts': [[2022, 9, 9]], 'date-time': '2022-09-09T15:48:08Z', 'timestamp': 1662738488467}, 'reference-count': 0, 'publisher': 'Springer Science and Business Media LLC', 'issue': 'S2', 'license': [ { 'start': { 'date-parts': [[2022, 6, 1]], 'date-time': '2022-06-01T00:00:00Z', 'timestamp': 1654041600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': ''}, { 'start': { 'date-parts': [[2022, 6, 1]], 'date-time': '2022-06-01T00:00:00Z', 'timestamp': 1654041600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': ''}], 'content-domain': {'domain': [''], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2022, 6]]}, 'DOI': '10.1007/s11606-022-07653-8', 'type': 'journal-article', 'created': {'date-parts': [[2022, 6, 17]], 'date-time': '2022-06-17T15:03:40Z', 'timestamp': 1655478220000}, 'page': '129-664', 'update-policy': '', 'source': 'Crossref', 'is-referenced-by-count': 133, 'title': 'Abstracts from the 2022 Annual Meeting of the Society of General Internal Medicine', 'prefix': '10.1007', 'volume': '37', 'member': '297', 'published-online': {'date-parts': [[2022, 6, 17]]}, 'container-title': 'Journal of General Internal Medicine', 'original-title': [], 'language': 'en', 'link': [ { 'URL': '', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': '', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': '', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 7, 5]], 'date-time': '2022-07-05T14:25:06Z', 'timestamp': 1657031106000}, 'score': 1, 'resource': {'primary': {'URL': ''}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 6]]}, 'references-count': 0, 'journal-issue': {'issue': 'S2', 'published-print': {'date-parts': [[2022, 6]]}}, 'alternative-id': ['7653'], 'URL': '', 'relation': {}, 'ISSN': ['0884-8734', '1525-1497'], 'subject': ['Internal Medicine'], 'container-title-short': 'J GEN INTERN MED', 'published': {'date-parts': [[2022, 6]]}, 'assertion': [ { 'value': '17 June 2022', 'order': 1, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': 'This content has been made available to all.', 'name': 'free', 'label': 'Free to read'}]}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop